Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Barry Abelson IV, M.D.,C.M.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rodriguez JD, Wallstrom G, Narayanan D, Welch D, Abelson MB. An Alternative Psychophysical Diagnostic Indicator of the Aging Eye. J Ophthalmol. 2019; 2019:2036192. PMID: 31781372.
    Citations:    
  2. Gomes PJ, Abelson MB, Stein L, Viirre E, Villafranca JE, Lasser EC. Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCubeĀ®: a randomized clinical trial. J Asthma Allergy. 2019; 12:71-81. PMID: 30881050.
    Citations:    
  3. Rodriguez JD, Lane K, Hollander DA, Shapiro A, Saigal S, Hertsenberg AJ, Wallstrom G, Narayanan D, Angjeli E, Abelson MB. Cone photoreceptor macular function and recovery after photostress in early non-exudative age-related macular degeneration. Clin Ophthalmol. 2018; 12:1325-1335. PMID: 30100705.
    Citations:    
  4. Rodriguez JD, Lane KJ, Ousler GW, Angjeli E, Smith LM, Abelson MB. Blink: Characteristics, Controls, and Relation to Dry Eyes. Curr Eye Res. 2018 01; 43(1):52-66. PMID: 29043838.
    Citations:    Fields:    Translation:Humans
  5. Ousler GW, Rimmer D, Smith LM, Abelson MB. Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review. Ophthalmol Ther. 2017 Dec; 6(2):263-276. PMID: 28956287.
    Citations:    
  6. Corcoran P, Hollander DA, Ousler GW, Angjeli E, Rimmer D, Lane K, Abelson MB. Dynamic Sensitivity of Corneal TRPM8 Receptors to Menthol Instillation in Dry Eye Versus Normal Subjects. J Ocul Pharmacol Ther. 2017 11; 33(9):686-692. PMID: 28933582.
    Citations:    Fields:    Translation:HumansCells
  7. Angjeli E, Gomes P, Lane KJ, Stein L, Abelson MB. Technical and clinical validation of the Allergen BioCubeĀ® for timothy grass. Immun Inflamm Dis. 2017 03; 5(1):78-84. PMID: 28250927.
    Citations:    Fields:    Translation:HumansAnimals
  8. Torkildsen G, Abelson MB, Gomes PJ, McLaurin E, Potts SL, Mah FS. Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model. J Ocul Pharmacol Ther. 2017 03; 33(2):79-90. PMID: 28072552.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  9. Gomes PJ, Lane KJ, Angjeli E, Stein L, Abelson MB. Technical and clinical validation of an environmental exposure unit for ragweed. J Asthma Allergy. 2016; 9:215-221. PMID: 28008277.
    Citations: 1     
  10. Zuberbier T, Abelson MB, Akdis CA, Bachert C, Berger U, Bindslev-Jensen C, Boelke G, Bousquet J, Canonica GW, Casale TB, Jutel M, Kowalski ML, Madonini E, Papadopoulos NG, Pfaar O, Sehlinger T, Bergmann KC. Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. J Allergy Clin Immunol. 2017 Apr; 139(4):1158-1166. PMID: 27697498.
    Citations: 3     Fields:    Translation:HumansAnimals
  11. Rodriguez JD, Lane KJ, Ousler GW, Angjeli E, Smith LM, Bateman KM, Abelson MB. Diurnal Tracking of Blink and Relationship to Signs and Symptoms of Dry Eye. Cornea. 2016 Aug; 35(8):1104-11. PMID: 27261939.
    Citations: 3     Fields:    Translation:Humans
  12. Ousler GW, Rodriguez JD, Smith LM, Lane KJ, Heckley C, Angjeli E, Abelson MB. Optimizing Reading Tests for Dry Eye Disease. Cornea. 2015 Aug; 34(8):917-21. PMID: 26075460.
    Citations: 1     Fields:    Translation:Humans
  13. Abelson MB, Shetty S, Korchak M, Butrus SI, Smith LM. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opin Pharmacother. 2015 Jun; 16(8):1219-31. PMID: 25943976.
    Citations: 3     Fields:    Translation:HumansCells
  14. Rodriguez JD, Lane KJ, Ousler GW, Angjeli E, Smith LM, Abelson MB. Automated Grading System for Evaluation of Superficial Punctate Keratitis Associated With Dry Eye. Invest Ophthalmol Vis Sci. 2015 Apr; 56(4):2340-7. PMID: 26066593.
    Citations: 2     Fields:    Translation:Humans
  15. Rodriguez JD, Lane K, Ousler GW, Angjeli E, Smith L, Abelson M. Automated Grading System for Evaluation of Corneal Superficial Punctate Keratitis Associated with Dry Eye. Invest Ophthalmol Vis Sci. 2015 Mar 03. PMID: 25736787.
    Citations:    
  16. Ousler GW, Abelson MB, Johnston PR, Rodriguez J, Lane K, Smith LM. Blink patterns and lid-contact times in dry-eye and normal subjects. Clin Ophthalmol. 2014; 8:869-74. PMID: 24833893.
    Citations: 2     
  17. Rodriguez JD, Johnston PR, Ousler GW, Smith LM, Abelson MB. Automated grading system for evaluation of ocular redness associated with dry eye. Clin Ophthalmol. 2013; 7:1197-1204. PMID: 23814457.
    Citations: 8     
  18. Abelson M. Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience. Cardiovasc J Afr. 2013 May; 24(4):107-9. PMID: 24217039.
    Citations: 2     Fields:    Translation:Humans
  19. Rodriguez JD, Ousler GW, Johnston PR, Lane K, Abelson MB. Investigation of extended blinks and interblink intervals in subjects with and without dry eye. Clin Ophthalmol. 2013; 7:337-42. PMID: 23439943.
    Citations: 4     
  20. Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB. The interblink interval in normal and dry eye subjects. Clin Ophthalmol. 2013; 7:253-9. PMID: 23403736.
    Citations: 9     
  21. Gomes PJ, Ousler GW, Welch DL, Smith LM, Coderre J, Abelson MB. Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy. Clin Ophthalmol. 2013; 7:157-65. PMID: 23378734.
    Citations: 4     
  22. Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther. 2011 Aug; 27(4):385-93. PMID: 21649522.
    Citations: 1     Fields:    Translation:Humans
  23. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011 Jun; 11(3):205-11. PMID: 21437647.
    Citations: 3     Fields:    Translation:Humans
  24. Abelson MB, Maffei C, Dewey-Mattia D. The Secrets to Sustained Release. Review of Ophthalmology. 2010; 17(1):38-40.
  25. Abelson M, Roos J. Mechanical embolectomy for large vessel ischemic strokes: a cardiologist's experience. Catheter Cardiovasc Interv. 2010 Sep 01; 76(3):309-15. PMID: 20506287.
    Citations:    Fields:    Translation:Humans
  26. Clark JC, Williams JI, Gow JA, Abelson MB, McNamara TR, Wheeler W, Shah S, Wheeler W, Lieberman P, Meltzer EO, Tort MJ, Zilberberg MD, Jacobsen T, Tillotson G, Zilberberg MD, Jacobsen T, Tillotson G, McNamara TR, Macejko TT, Meier EJ, Bergmann MT, Williams JI, Gow JA. Research abstracts presented at the Eastern Allergy Conference, Palm Beach, Florida, May 6-9, 2010. Allergy Asthma Proc. 2010 Jul 01; 31(4):361-362. PMID: 29165186.
    Citations:    Fields:    
  27. Abelson MB. Personal profile. Mark B. Abelson, MD, CM, FRCSC. Ocul Surf. 2010 Jul; 8(3):154-6. PMID: 20712972.
    Citations:    Fields:    Translation:Humans
  28. Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol. 2010 Jul; 105(1):57-64. PMID: 20642205.
    Citations: 2     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  29. Walker PM, Lane KJ, Ousler GW, Abelson MB. Diurnal variation of visual function and the signs and symptoms of dry eye. Cornea. 2010 Jun; 29(6):607-12. PMID: 20458235.
    Citations: 16     Fields:    Translation:Humans
  30. Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol. 2010 Jul; 150(1):122-127.e5. PMID: 20488431.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  31. Maffei CJ, Ousler III GW, Welch DL, Curwen SJ, Prifogle E, Abelson MB. Time to reflex tearing in response to chemical nasolacrimal stimulus in dry eye subjects versus normals. Association for Research in Vision and Ophthalmology Meeting. 2010.
  32. Angjeli E, Rodriguez J, Lane KJ, Abelson MB, Ousler III GW. Evaluation of Enhanced OPI; Using computerized video tracking of tear film break up for evaluation of tear film stability. Association for Research in Vision and Ophthalmology Meeting. 2010.
  33. Ousler III GW, Abelson MB, Welch DL. Enhanced precision of the Controlled Adverse Environment (CAE) system. Association for Research in Vision and Ophthalmology Meeting. 2010.
  34. Crawford KS, Gaines P, Breton SL, Chim HB, Lane KJ, Abelson MB. Comparative assessment of murine allergic conjunctivitis model variations for efficinet pre-clinical screening. Association for Research in Vision and Ophthalmology Meeting. 2010.
  35. White R, Rodriguez J, Lane KJ, Johnson P, Angjeli E, Abelson MB. Blink patterns in normal and dry eye subjects; Beyond blink rate. Association for Research in Vision and Ophthalmology Meeting. 2010.
  36. Breton S, Lane KJ, Gomes PJ, Shapiro A, Ousler III GW, Welch D, Abelson MB. Development of a redness scale for morning eye congestion. Association for Research in Vision and Ophthalmology Meeting. 2010.
  37. Hsu H-C, Patane M, Ousler III GW, Kennedy K, Johnston P, Abelson R. Leveraging phase II study data to effectively select primary endpoints and sample size for a phase III study. Association for Research in Vision and Ophthalmology Meeting. 2010.
  38. Gow JA, Williams JI, Gomes PJ, Abelson MB, McNamara TR. Rhinorrhea reduction using bepreve ophthalmic solution 1.5% in a clinical model of allergic conjunctivitis: An analysis of pooled data from two phase 3 conjunctival allergen challene (CAC) clinical trials. Association for Research in Vision and Ophthalmology Meeting. 2010.
  39. Rodriguez J, Angejeli E, Lane KJ, White R, Breton S, Abelson MB. Correlation between bllink rate, tear film corneal protection, and corneal staining. Association for Research in Vision and Ophthalmology Meeting. 2010.
  40. Abelson MB, Lane KJ, Maffei C. Code red: The key features of hyperemia. Review of Ophthalmology. 2010; 17(4):92-4.
  41. Abelson MB, Abelson R, Dewey-Mattia D. Clinical confounders. Review of Cornea and Contact Lens. 2010; 12.
  42. Abelson MB, Gomes P, Chaturvedi R. Production of an acute and late--phase response in allergic rhinitis in ian Allergen BioCube. American Academy of Allergy, Asthma & Immunology Meeting. 2010.
  43. McNamara TR, Williams JI, Gow JA, Gomes PJ, Abelson MB. . Bepreve 1.5% reduces rhinorrhea for at least 16 hours: An integrated analysis of two phase 3 Conjunctival Alelrgen Challenge (CAC) clinical trials. American Academy of Allergy, Asthma & Immunology Meeting. 2010.
  44. Abelson MB, Shapiro A. The many faces of adenovirus. Review of Ophthalmology. 2010; 17(3):66-9.
  45. Abelson MB, Lane KJ, Maffei CJ. Examining the red eye. Review of Cornea and Contact Lens. 2010; 14-15.
  46. Gomes P, Abelson MB, Mandell K. Perennial allergen skin sensitivity as a predictor of seasonal allergic rhinoconjunctivitis severity. American Academy of Allergy, Asthma & Immunology Meeting. 2010.
  47. Gow JA, Williams JI, McNamara TR, Gomes PJ, Abelson MB. Bepreve 1.5% reduces nasal congestion for at least 16 hours: an analysis of integrated data from two phase 3 Conjunctival Allergen Challenge (CAC) clinical trials. American Academy of Allergy, Asthma & Immunology Meeting. 2010.
  48. Abelson MB, Howe AJ, Maffei C, Shapiro A. A Fresh Perspective on Meibomitis. Review of Ophthalmology. 2010; 17(2):74-77.
  49. Abelson MB, Maffei C, Howe AJ. Why Doesn't the Ocular Drug Work?. Review of Ophthalmology. 2009; 16(12):42-44, 65.
  50. Abelson MB, Dewey-Mattia D, Maffei C, Ousler G, Shapiro A. New Treatments may improve dry eye care. Optometry Times. 2009; 14-15.
  51. Abelson MB, Mandell KJ, Howe A. When Tight Junctions Aren't Tight Enough. Review of Ophthalmology. 2009; 16(11):68-70.
  52. Abelson MB, Dewey-Mattia D. Recognizing Iritis. Review of Cornea and Contact Lens. 2009.
  53. Abelson MB, Mandell KJ, Shapiro A, Howe AJ. Should You Administer The Herpes Vaccine?. Review of Ophthalmology. 2009; 16(10):100-103.
  54. Abelson MB. Remembering Dr. Jeffrey Gilbard. Review of Ophthalmology. 2009; 16(10):104.
  55. Abelson MB, Tzekov R, Sena D, Lou P, Dewey-Mattia D. Address diabetic retinopathy by treating underlying disease. Ophthalmology Times. 2009; 28-32.
  56. Abelson MB, Tzekov R, Lou P, Sena D, Dewey-Mattia D. Emerging technology aids diabetic ritinopathy screening. Ophthalmology Times. 2009.
  57. Abelson MB, Ousler GW, Maffei C. Dry eye: through the years in tears. Review of Ophthalmology. 2009; 16(9):72-74.
  58. Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009 Sep; 31(9):1908-21. PMID: 19843481.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  59. Abelson MB, Howe AJ. MEMS and lenses. Review of Cornea and Contact Lens. 2009.
  60. Abelson MB, Tzekov RT, Howe AJ. Gene therapy turns foes into friends. Review of Ophthalmology. 2009; 16(8):56-58.
  61. Abelson MB, Ousler GW, Maffei C. Dry eye in 2008. Curr Opin Ophthalmol. 2009 Jul; 20(4):282-6. PMID: 19398910.
    Citations: 10     Fields:    Translation:Humans
  62. Abelson MB. ARVO brandishes the cutting edge. Review of Ophthalmology. 2009; 16(7):44-48.
  63. Tzekov RT, Abelson MB, Dewey-Mattia D. New Advances in Back of the Eye Drug Delivery. Retina Today. 2009; 1-5.
  64. Abelson MB, Dewey-Mattia D. Finding New Uses for Ancient Drugs. Review of Ophthalmology. 2009; 16(6):64-67.
  65. Abelson MB. Allergy control. Review of Cornea and Contact Lens. 2009.
  66. Abelson MB, Ousler III GW, Maffei C. Dry eye in 2008. Current Opinion in Ophthalmology. 2009; 20:282-6.
  67. Gow JA, Torkildsen GL, Williams JI, Gomes PJ, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution 1.05 rapidly reduces conjunctival hyperemia in the Conjunctival Allergen Challenge (CAC) model of acute allergic conjunctivitis. Association for Research in Vision and Ophthalmology Meeting. 2009.
  68. Kurata FK, Macejko TT, Meier EJ, Bergmann MT, McLaurin EB, Williams JI, gow, JA, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution 1.5% reduces tearing at 8 hours following dosing in a multi-site cllinical trial using the Conjunctival Allergen Challenge (CAC) model of acute allergic conjunctivitis. Association for Research in Vision and Ophthalmology Meeting. 2009.
  69. Abelson MB, Tzekov RT, Ousler GW, Shapiro A, Howe AJ, Maffei CJ. Pharmaceutical pipeline trying to address underserved areas of ophthalmology. Ophthalmology Times. 2009; 1:16-18.
  70. Abelson MB, Ousler G, Welch D, Nentwig B. Symptomatic break-up time (SBUT) in dry eye patients with normal vs. low corneal sensitivity. Association for Research in Vision and Ophthalmology Meeting. 2009.
  71. Macejko TT, McLaurin EB, Kurata FK, Meler EJ, Bergmann MT, Torkildsen GL, Gow JA, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching following dosing in the Conjunctival Allergen Challenge (CAC) model of acute allergic conjunctivitis. Association for Research in Vision and Ophthalmology Meeting. 2009.
  72. Gomes P, Abelson MB. Bepotastine besilate ophthalmic solution 1.0% rapidly reduces conjunctival hyperemia in the Conjunctival Allergen Challenge (CAC) model of acute allergic conjunctivitis. Association for Research in Vision and Ophthalmology Meeting. 2009.
  73. Protzko EE, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR. The safety of the anti-histamine bepotastine besilate ophthalmic solution in a healthy pediatric population from ten to seventeen years of age. Association for Research in Vision and Ophthalmology Meeting. 2009.
  74. Abelson MB, Howe AJ, Gomes PJ, Guhlati A. More than "just an annoyance.". Review of Cornea and Contact Lens. 2009.
  75. Abelson MB, Lilyestrom LJ. Iodine: An Elemental Force Against Infection. Review of Ophthalmology. 2009; 16(5):80-3.
  76. Ousler G, Canova M, Nentwig B, Welch D, Abelson MB. Modification of tear film break-up pattern (TFBUP) in the Controlled Adverse Environment (CAE) model. Association for Research in Vision and Ophthalmology Meeting. 2009.
  77. Plumer A, Rosenthal A, Gulati A, Gomes P, Welch D, Abelson MB. Evaluation of daily ocular and nasal allergic signs and symptoms during 4 weeks of ragweed season in untreated allergic conjunctivits and rhinitis subjects. Association for Research in Vision and Ophthalmology Meeting. 2009.
  78. Curwen S, Ousler G, Nentwig B, Welch D, Abelson MB. Effect of Lacrisert(R) on the signs and symptoms of dry eye in contact lens wearers. Association for Research in Vision and Ophthalmology Meeting. 2009.
  79. Ousler G, Welch D, Abelson MB. Evaluation of functional visual performance using the IVAD method with currently marketed artificial tear products. Association for Research in Vision and Ophthalmology Meeting. 2009.
  80. Bergmann MT, Gomes PJ, Williams JI, Gow JA, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a multi-site clinical model of allergic conjunctivitis. American Society of Cataract and Refractive Surgery Meeting. 2009.
  81. Williams JI, Torkildsen GL, Gomes PJ, Gow JA, Abelson MB, McNamara TR. Effect of bepotastine besilate ophthalmic solution (1.0% and 1.5%) on eyelid swelling in a clinical model of allergic conjunctivitis. American Society of Cataract and Refractive Surgery Meeting. 2009.
  82. McNamara TR, Comes PJ, Abelson MB, Williams JI, Gow JA, Torkildsen GL. Effectiveness of bepotastine besilate ophthalmic solution 1.5% in reducing ocular itching in al allergic conjunctivitis model. American Society of Cataract and Refractive Surgery Meeting. 2009.
  83. Abelson MB, HOwe AJ, Lane KJ, Gomes PJ. An Eye-Opening Look at "Morning Eye.". Review of Ophthalmology. 2009; 16(4):86-88.
  84. Abelson MB, Howe AJ. A Clinical Profile of VKC. Review of Cornea and Contact Lens. 2009.
  85. Abelson MB, Howe AJ. A Clinical Profile of VKC. Review of Cornea and Contact Lens. 2009.
  86. Abelson MB, Dewey-Mattia D. Sjogren's Syndrome and Dry Eye, Part Two. Review of Cornea and Contact Lens. 2009.
  87. Abelson MB, Howe AJ. Serendipitous Drug Development. Review of Ophthalmology. 2009; 16(3):54-57.
  88. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia. 2009 Feb; 50(2):163-73. PMID: 19230067.
    Citations: 37     Fields:    Translation:Humans
  89. Abelson MB, Dewey-Mattia D, Crawford K. The Secret World of Pharmacokinetics. Review of Ophthalmology. 2009; 16(2):58-61.
  90. Abelson MB, Dewey-Mattia D. Sjogren's Syndrome and Dry Eye, Part One. Review of Cornea and Contact Lens. 2009.
  91. William JI, Gow, JA, Torkildsen GL, Gomes PJ, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution reduces nasal symptoms in the Conjunctival Allergen Challenge (CAC) clinical model. Western Society of Allergy, Asthma, and Immunology Meeting. 2009.
  92. Abelson MB, Torkildsen GL, Williams JI, et al. Time to Onset and Duration of Action of the Antihistamine Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% in Allergic Conjunctivitis: A Phase III, Single-Center, Prospective, Randomized, Double-Masked, Placebo-Controlled, Conjunctival Allergen Challenge Assesment in Adults and Children. Clinical Therapeutics. 2009.
  93. Walker PM, Lane KJ, Ousler GW III, Abelson MB. Diurnal variation of visual function and the signs and symptoms of dry eye. Cornea. 2009.
  94. Abelson MB. An Elastic Defense vs. Corneal Damage. Review of Ophthalmology. 2009; 16(1):64-67.
  95. Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc. 2008 Nov-Dec; 29(6):644-53. PMID: 19063816.
    Citations: 4     Fields:    Translation:Humans
  96. Mahr T, Rosenwasser L, Abelson MB, Gomes PJ, Greiner JV. A comparison of olopatadine 0.2% ophthalmic solution (Pataday) versus fluticasone furoate nasal spray (Veramyst) for the treatment of allergic conjunctivitis. American College of Allergy, Asthma, and Immunology Annual Meeting. 2008.
  97. Tumaian E, Abelson MB, Gomes P, Kennedy K, Wall M. An evaluation of the efficy of olopatadine 0.2% (Pataday) in a modified conjunctival allergen challenge model. American College of Allergy, Asthma, and Immunology Annual Meeting. 2008.
  98. Chun DK, Shapiro A, Abelson MB. Ocular Pharmacokinetics. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:179-192.
  99. Abelson MB, Dewey-Mattia D, Shapiro A. Acanthamoeba: A Dangerous Pathogen. Review of Ophthalmology. 2008; 15(11):110-114.
  100. Abelson MB, Butrus S. Corticosteroids in Ophthalmic Practice. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:249-258.
  101. Abelson MB Howe AJ, Capriotti J, Shapiro A. Get To Know Your Antiseptic Options. Review of Ophthalmology. 2008; 15(12):64-67.
  102. Berdy GJ, Leonardi A, Abelson MB. Antihistamines and Mast Cell Stabilizers in Allergic Ocular Disease. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:265-280.
  103. Abelson MB, Torkildsen GL, Udell IJ. Allergic and Toxic Reactions: The Immune Response. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:611-624.
  104. To KW, Abelson MB, Neufeld AH. Nonsteroidal Anti-inflammatory Drugs. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:259-264.
  105. Abelson MB. Defining Dry Eye. Review of Cornea & Contact Lenses. 2008; (11):6.
  106. Abelson MB, Doane MG, Ousler G. Tear Film and Blink Dynamics. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:281-286.
  107. Abelson MB, Shapiro A, Maffei C. Questions remain regarding antibacterial therapy. Ophthalmology Times. 2008; (11).
  108. Torkildsen GL, Gomes PJ, Williams JI, Gow JA, Abelson MB, McNamara Tr. Evaluation of bepotastine besilate ophthalmic solution 1.0% in the conjunctival allergen challenge model of allergic conjunctivitis. American Academy of Ophthalmology Meeting. 2008.
  109. Abelson MB, Ousler G, Anderson R. Tear Substitutes. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2008; 1:287-292.
  110. Abelson MB, Lilyestrom L. The Whipsaw of Allergic Dry Eye. Review of Ophthalmology. 2008; 15(10):94-98.
  111. Abelson MB, Forte J, Shapiro A. MRSA: It's Not Just Resistant to Methicillin. Review of Ophthalmology. 2008; 15(9):82-85.
  112. Abelson MB, Gomes P, Lilyestrom L, Taylor A. When Allergic Conditions Collide. Review of Ophthalmology. 2008; 15(8):68-71.
  113. Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proceedings. 2008; 29:644-653.
  114. Abelson MB. Oral Treatment Options Abound for Dry Eye. Ophthalmology Times. 2008.
  115. Torkildsen GL, Abelson MB, Gomes PJ. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther. 2008 Jul; 30(7):1272-82. PMID: 18691986.
    Citations: 2     Fields:    Translation:Humans
  116. Abelson MB, Welch D. Innovation takes center stage at ARVO 2008 meeting. Ophthalmology Times. 2008; 33(15):16-17.
  117. Abelson, ORA Clinical R&D Staff. What We Leaned at ARVO 2008. Review of Ophthalmology. 2008; 15(7):74-78.
  118. Abelson MB, Shapiro A, Makino A, Lane K. The Other Side of Antibiotics. Review of Ophthalmology. 2008; 15(6):70-73.
  119. Abelson MB, Heller W, Shapiro AM, et al. Clinical cure of bacterial conjunctivitis with azithromycin 1%: Vehicle-controlled, double-masked clinical trial. American Journal of Ophthalmology. 2008; 146(6):959-65.
  120. Abelson MB, Lilyestron L. What Makes Up a Mast Cell?. Review of Cornea & Contact Lenses. 2008; (June):13.
  121. Ousler GW, Hagberg KW, Schindelar M, Welch D, Abelson MB. The Ocular Protection Index. Cornea. 2008 Jun; 27(5):509-13. PMID: 18520496.
    Citations: 22     Fields:    Translation:Humans
  122. Abelson MB, Lilyestron L. Irritating Infiltrates. Review of Cornea & Contact Lenses. 2008; (May):9.
  123. Abelson MB, Maffei C. What's Driving Patients Toward Homeopathy?. Review of Ophthalmology. 2008; 15(5):100-103.
  124. Lane KJ, Walker P, Ousler GW, White R, Abelson MB. The Effect of Increased Blink Rate on Visual Performance in Dry Eye Patients. Association for Research in Vision and Ophthalmology Meeting. 2008.
  125. Ousler GW, Power D, Schindelar M, Welch D, Abelson MB. A Phase II Double-Masked, Randomized, Parallel-Group Study to Assess the Safety and Efficacy of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) in Dry Eye Patients Exposed to the Controlled Adverse Environment (CAE). Association for Research in Vision and Ophthalmology Meeting. 2008.
  126. Abelson MB, Edwards MR, Vogelson C, Pasquine T, Robertson SM. Effects of Olopatadine Hydrochloride Ophthalmic Solution, 0.2% (PatadayTM)on the Ocular Itching and Redness Associated With Allergic Conjunctivitis or Rhinoconjunctivitis. Association for Research in Vision and Ophthalmology Meeting. 2008.
  127. Schindelar MR, Prifogle E, Ousler GW, Maffei C, Abelson MB. Diurnal Variations in Symptoms of Dry Eye. Association for Research in Vision and Ophthalmology Meeting. 2008.
  128. Walker PM, Ousler GW, Lane K, White R, Welch D, Abelson MB. A Comparative Investigation of Spontaneous Blink Rates Across a Series of Tasks in Dry Eye and Control Patients. Association for Research in Vision and Ophthalmology Meeting. 2008.
  129. Abelson MB, Pfleger M, Casavant JS, Lilyestrom L, Leung S. Regulation of Registration. EyeWorld. 2008; (May).
  130. Abelson MB. Scientific Rigor Needed. Review of Cornea and Contact Lenses. 2008; (April).
  131. Abelson MB, Leung S. The Many Faces of Chlamydial Infection. Review of Ophthalmology. 2008; 15(4):84-87.
  132. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008 Apr; 4(4):453-61. PMID: 18433347.
    Citations: 6     Fields:    Translation:Humans
  133. Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008 Jun; 145(6):959-65. PMID: 18374301.
    Citations: 15     Fields:    Translation:HumansCells
  134. Abelson MB, Neufeld AH, Folkman J. The Rabbi-like Doctor. Retinal Physician. 2008.
  135. Abelson MB, Lilyestrom L. "Mad Eye Disease": Should You Worry?. Review of Ophthalmology. 2008; 15(3):94-98.
  136. Abelson MB, Gomes P, Leung S. Ocular Itching, Redness Key to Diagnosing Allergic Conjunctivitis. Primary Care Optometry News. 2008.
  137. Abelson MB, Leung S. The Yin and Yang of The Adenovirus. Review of Ophthalmology. 2008; 15(2):82-85, 105.
  138. Abelson MB. Does allergy article pass this challenge test? Letter to the Editor. Review of Ophthalmology. 2008; 15(2).
  139. Abelson MB, Leung S. Are You Probiotic?. Review of Cornea & Contact Lenses. 2008; (January/February):8.
  140. Abelson MB, Kennedy K, Lilyestrom L. Unraveling the Mystery of Endophthalmitis. Review of Ophthalmology. 2008; 15(1):60-63.
  141. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res. 2007 Dec; 32(12):1017-22. PMID: 18085465.
    Citations: 9     Fields:    Translation:Humans
  142. Abelson MB, Sullivan DA, Ousler GW, Smith L, Maffei C. What You Missed at the TFOS Meeting. Review of Ophthalmology. 2007; 14(12):56-61.
  143. Abelson MB, Welch CL, Walker PM. Quality of Life with Dry Eye. Review of Cornea & Contact Lenses. 2007; 6.
  144. Abelson MB, Lilyestrom L. Melting Away the Myths of NSAIDs. Review of Ophthalmology. 2007; 14(11):124-128.
  145. Abelson MB, Ousler G, Lilyestrom L. Puffery Versus Scientific Integrity. Review of Cornea & Contact Lenses. 2007; (10):8.
  146. Abelson MB, Workman A, Taylor A. Eavesdropping on Blepharitis. Review of Ophthalmology. 2007; 14(10):92-96.
  147. Abelson MB, McLaughlin J. The Future of RPE Transplantation. Review of Ophthalmology. 2007; 14(9):72-75.
  148. Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007 Aug; 48(8):3425-9. PMID: 17652708.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  149. Abelson MB, Walker P. Breaking Down The Blink. Review of Ophthalmology. 2007; 14(8):68-71.
  150. Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proceedings. 2007; 28(4):427-433.
  151. Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 2007 Jul-Aug; 28(4):427-33. PMID: 17883910.
    Citations: 1     Fields:    Translation:Humans
  152. Abelson MB, Welch D, McLaughlin J, Anderson R, Lilyestrom L, Taylor A. What We Learned at ARVO: 2007. Review of Ophthalmology. 2007; 14(7):70-74.
  153. Abelson MB, Plumer A. Target Allergens with the Body's Defenses. Review of Ophthalmology. 2007; 14(6):76-78, 92.
  154. Abelson M, Protzko E, Shapiro A, Garces-Soldana A, Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007 Jun; 1(2):177-82. PMID: 19668507.
    Citations: 8     
  155. Abelson MB, Walker PM. Allergy and Contact Lens Wear. Review of Cornea & Contact Lenses. 2007; 10.
  156. Walker P, Ousler GW, Workman DA, Hankin M, Abelson MB. Visual Function in Normals Compared to Patients Diagnozed With Dry Eye as Measured by the Inter-Blink Interval Visual Acuity Decay (IVAD) Test. Association for Research in Vision and Ophthalmology Meeting. 2007.
  157. Workman DA, Ousler GW, Abelson MB. Age Related Differences in Lid Margin Health. Association for Research in Vision and Ophthalmology Meeting. 2007.
  158. Cumberlidge G, Saragovi H, Lane KJ, Abelson MB. An Evaluation of D3, a Novel TrkA Receptor Agonist for Ability to Prevent Retinal Ganglion Cell Loss in a Rat Model of Glaucoma. Association for Research in Vision and Ophthalmology Meeting. 2007.
  159. Krokhmal L, Gomes P, Welch D, Abelson MB. The Incidence of Dry Eye With Topical Anti-Allergic Therapies. Association for Research in Vision and Ophthalmology Meeting. 2007.
  160. Crampton J, Abelson MB, Ousler GW, Pflugfelder S, De Paiva C, Forbes M, Power D. Correlation of the Controlled Adverse Environment (CAE) Model With a Murine Model of Experimental Dry Eye in Assessing the Ability of Topical Doxycycline to Prevent Corneal Barrier Disruption. Association for Research in Vision and Ophthalmology Meeting. 2007.
  161. Abelson MB, McLaughlin J. Allergy: The Search for Therapeutic Targets. Review of Ophthalmology. 2007; 14(5):106-108.
  162. Chaturvedi R, Gomes PJ, Welch D, Abelson MB. A Retrospective Analysis of the Predictive Value of Skin Tests Used in Subjects Screened in the Conjunctival Allergen Challenge Model. Association for Research in Vision and Ophthalmology Meeting. 2007.
  163. Ousler GW, Brazzell K, Durham T, Walker P, Anderson RT, Abelson MB. A Correlation Between Central Corneal Staining and Visual Function in Patients Diagnosed With Dry Eye. Association for Research in Vision and Ophthalmology Meeting. 2007.
  164. Abelson MB, Taylor A. Effect of Dosing Frequency on Patient Compliance. Review of Cornea & Contact Lenses. 2007; 8.
  165. Abelson MB, McLaughlin J. Inside the Cell: The Secrets of Steroids. Review of Ophthalmology. 2007; 14(4):122-124.
  166. Abelson MB, Lilyestrom L. Ocular Encounters of the Viral King. Review of Ophthalmology. 2007; 14(3):76-80.
  167. Abelson MB, Lilyestrom L. Drug-inducted Allergic Conjunctivitis. Review of Cornea & Contact Lenses. 2007; 8.
  168. Abelson MB, Lilyestrom. Paving the Pastures: Urban Life and Allergy. Review of Ophthalmology. 2007; 14(2):86-88.
  169. Abelson MB, Walker PM. A Colorful Future for Vision Testing. Review of Ophthalmology. 2007; 14(1):48-52.
  170. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen Challenge. Current Eye Research. 2007; 32:1017-1022.
  171. Abelson MB, Protzko E, Shapiro A, Graces-Soldana A, Gowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs. tobramycin in adult and pediatric subjects and bacterial conjunctivitis. Clinical Ophthalmology. 2007; 1(2):177-182.
  172. Abelson MB, Anderson R. SBUT and OPI Two Diagnostics to help us understand and stop the vicious cycle of dry eye. Review of Cornea & Contact Lenses. 2007; 8.
  173. Abelson MB, Walker P, Ousler GW, Plumer A. Dry Eye Diagnosis: It's All a Blur. Review of Ophthalmology. 2006; 13(12):50-52.
  174. Abelson MB, Anderson R. Demystifying Dumulcents. Review of Ophthalmology. 2006; 13(11):122-126.
  175. Abelson MB, Hartnett ME, McLaughlin J. Cutting-Edge Therapies for Wet AMD. Review of Ophthalmology. 2006; 13(10):100-102.
  176. Abelson MB, Ousler GW, Anderson R. Relieving Dry Eye Symptoms by Controling Common Environmental Factors. Refractive Eyecare. 2006; 10(11).
  177. Abelson MB, Mertz P, Ziyadeh N. The Hassles of Hypoxia. Review of Cornea & Contact Lenses. 2006; 8.
  178. Abelson MB, Ousler G, Anderson R. Simple Clinical Tips for Better Dry Eye Diagnoses. Ophthalmology Management. 2006.
  179. Abelson MB, Ousler G, Anderson R. Diagnostic Innovation for Dry Eye. EyeWorld. 2006.
  180. Abelson MB, Fink K. Fusarium Outbreak: Lessons Learned. Review of Ophthalmology. 2006; 13(9):88-90.
  181. Abelson MB, Anderson A. Tear Substitutes and Science. Review of Cornea & Contact Lenses. 2006; 42-45.
  182. Abelson MB, Mertz P. Pingueculitis. Review of Cornea & Contact Lenses. 2006; 7.